Discovery Biology

Cytotoxicity and Mitochondrial Toxicity Assays Early Safety Biomarker Panels Detects cellular and mitochondrial stress responses, enabling early identification of safety

Caco-2 and PAMPA Permeability Transporter Panels (P-gp, BCRP, OATP) Determines compound permeability, efflux, and transport mechanisms across biological membranes, providing

Microsomal and Hepatocyte Stability Intrinsic Clearance CYP Inhibition/Phenotyping Plasma Protein Binding Metabolic Stability Assesses drug metabolism and disposition through microsomal

Signaling Viability Reporter Assays Pathway Readouts Evaluates cellular responses, pathway activation, and downstream signalling through viability, reporter, and mechanistic assays,

Biochemical (Enzyme/Receptor) Assays Binding Assays Confirms molecular targets and quantifies compound affinity through enzyme kinetics, receptor binding, and biochemical assays,

Confirms pharmacokinetic or pharmacodynamic interactions identified in-vitro through in-vivo verification, ensuring safety in combination therapies or co-administered regimens.

Determines safe and effective dosing ranges in animal systems, identifying preliminary efficacy and potential adverse effects to inform first-in-human dose

Rodent & Non-Rodent Models (Oncology, Infection, CNS, Cardiovascular, and Metabolic Diseases) Assesses the therapeutic potential of compounds using validated disease

Dose–Response Studies Exposure–Response Relationships Translational Modelling Integrates pharmacokinetic and pharmacodynamic data to determine optimal dose ranges, therapeutic indices, and biological

Single & Multiple Dose Pharmacokinetics Tissue Distribution & Toxicokinetics Evaluates the systemic exposure, clearance, and bioavailability of drug candidates through